Role of targeted therapy in metastatic colorectal cancer

doi:10.4251/wjgo.v8.i9.642

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11173)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

1001

WORD

341

HTML

7107

Tables (1-4)

217

Sum=8666

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1026

Download

1481

Sum=2507

Sep 15, 2016 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (73)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Sep 15, 2016; 8(9): 642-655
Published online Sep 15, 2016. doi: 10.4251/wjgo.v8.i9.642

Table 2 Clinical trials of anti-epidermal growth factor receptor therapies in metastatic colorectal cancer with KRAS wild type

Trial name	Regimens	n	ORR	PFS (mo)	OS (mo)
First-line chemotherapy
CRYSTAL	FOLFIRI + Cetuximab	316	57.3%	9.9	23.5
OPUS	FOLFOX + Cetuximab	159	57%	8.3	22.8
COIN	FOLFOX/CapeOX + Cetuximab	362	64%	8.6	17.0
NORDIC-VII	FLOX + Cetuximab	97	46%	7.9	20.1
PRIME	FOLFOX + Panitumumab	325	55%	9.6	23.9
Second-line, salvage-line chemotherapy, or beyond progression
20050181 trial	FOLFIRI + Panitumumab	303	36%	6.7	14.5
PICCOLO	Irinotecan + Panitumumab	230	34%	5.5	10.4
CO.17	Cetuximab	117	13%	3.7	9.5
20020408 trial	Panitumumab	124	17%	12.3 wk	8.1

ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; FOLFIRI: Bolus and infusional 5-fluorouracil/leucovorin/irinotecan; FOLFOX: Bolus and infusional 5-fluorouracil/leucovorin/oxaliplatin; CapeOX: Capecitabine/oxaliplatin; FLOX: Bolus 5-fluorouracil/leucovorin/oxaliplatin.

Citation: Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655
URL: https://www.wjgnet.com/1948-5204/full/v8/i9/642.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i9.642